Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues
Reexamination Certificate
1998-12-04
2002-05-28
Pak, Michael (Department: 1646)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Reexamination Certificate
active
06395876
ABSTRACT:
BACKGROUND OF THE INVENTION
This invention is generally in the field of tryptophan transporters, and more specifically is drawn to a novel tryptophan transport system.
Tryptophan occupies a unique position at the interface between the immune system and cellular metabolism. It is the only amino acid whose level is specifically and selectively modified in response to signals of infection and inflammation. This is accomplished by the enzyme indoleamine 2,3-dioxygenase (IDO), which rapidly and selectively degrades tryptophan following induction by interferon-&ggr; (IFN&ggr;) and other proinflammatory signals (Taylor and Feng, 1991
FASEB J.
5, 2516-2522). The IDO system, whose origins extend back to invertebrates (Suzuki, et al., 1996
Biochem. Biophys. Acta
1308, 41-48; Suzuki, 1994
J. Prot. Chem.
14, 9-13) is hypothesized to inhibit the replication of intracellular pathogens (Gupta, et al., 1994
Infect. Immun.
62, 2277-2284; Thomas, et al., 1993
J. Immunol.
150, 5529-5534) and to participate in the antiproliferative effect of interferons on host cells (Aune and Pogue, 1989
J. Clin. Invest.
84, 863-875; Feng and Taylor 1989,
Proc. Natl. Acad. Sci. USA,
86, 7144-7148; Ozaki, et al., 1988,
Proc. Natl. Acad Sci. USA
85, 1242-1246). Tryptophan is also unique in that it is the only amino acid whose entry into the protein synthetic pathway is regulated by the immune system. Like IDO, the gene for tryptophanyl-tRNA synthetase is highly induced by IFN&ggr; (Fleckner, et al., 1991
Proc. Natl. Acad. Sci. USA
88, 11520-11524; Fleckner, et al., 1995
Cytokine
7, 70-77; Rubin, et al., 1991
J. Biol. Chem.
266, 24245-24248), which has been proposed to assist cells in competing for scarce supplies of tryptophan (Kisselev, 1993
Biochimie
75, 1027-1039). These observations indicate that tryptophan metabolism plays an important role in host defense.
Activated macrophages display a marked induction of the tryptophan catabolic pathway (Werner, et al., 1987
Life Sci.
41, 273-280; Carlin, et al., 1989,
J. Leuk. Biol.
45, 29-34). These cells are capable of reducing the tryptophan concentration in their local microenvironment to such a low level that cellular proliferation becomes impossible. This mechanism underlies the ability of certain types of macrophages (Munn, et al., 1996
J. Immunol.
156, 523-532) to inhibit T cell activation. In order to achieve this effect, however, macrophages must reduce the tryptophan concentration to the low nanomolar range (less than 50 nM), three orders of magnitude below its normal level. Macrophages can continue to take up tryptophan efficiently at very low substrate concentrations, even when tryptophan is competing with multiple other amino acids, present at much higher concentrations, for transport into the cell.
Based on this analysis, it is postulated that there must be a specific, high affinity tryptophan transporter.
It is therefore an object of the present invention to provide a high-affinity amino acid transport system that is highly specific for tryptophan.
It is another object of the present description to provide methods and reagents for use in isolating and characterizing the cDNA and amino acid sequence of high affinity tryptophan transporters.
It is yet a still further object of the present invention to provide methods and reagents for designing and isolating molecules and drugs that can stimulate or inhibit the binding or transport of tryptophan with high affinity tryptophan transporters.
SUMMARY OF THE DISCLOSURE
A high affinity and extremely selective tryptophan transport system present in human monocyte-derived macrophages is disclosed. Human monocyte-derived macrophages include two distinct transporters, a high affinity (Km=290±160 nM) transporter that is highly specific for tryptophan and a low affinity (Km=27±4 &mgr;M) transporter that is less specific for tryptophan, consistent with the known system L. The tryptophan transport system is predominantly (86%) sodium-independent. The high-affinity system is very specific for tryptophan and shows no transport of any other essential amino acids in the tryptophan transport concentration range. This high-affinity system is expressed at very low levels in fresh monocytes, but undergoes a 10-30 fold induction during macrophage differentiation. This high affinity, tryptophan-selective transport system allows macrophages to take up tryptophan efficiently under conditions of very low substrate concentration, such as can occur at sites of inflammation.
Methods for the isolation of the cDNA that codes for this high affinity tryptophan transport system are described along with methods for the purification of the high affinity transporter. Methods for obtaining and using molecules which interact with the high affinity transporter are also described. Molecules which are obtained by their competitive binding properties with tryptophan for the high affinity transporter tryptophan binding site are also described. Also described are compositions, and methods for using these compositions, which do not competitively interact with tryptophan for the high affinity transporter tryptophan binding site.
REFERENCES:
patent: 4244946 (1981-01-01), Rivier et al.
patent: 4305872 (1981-12-01), Johnston et al.
patent: 4316891 (1982-02-01), Guillemin et al.
patent: 4629784 (1986-12-01), Stammer
patent: 4792525 (1988-12-01), Ruoslahti et al.
patent: 4868116 (1989-09-01), Morgan et al.
patent: 4980286 (1990-12-01), Morgan et al.
patent: 5244807 (1993-09-01), Murtfeldt et al.
patent: 5723325 (1998-03-01), Murtfeldt et al.
patent: 5874560 (1999-02-01), Kawakami et al.
patent: 0 385 385 (1990-09-01), None
patent: WO 93/01286 (1993-01-01), None
Attwood, “The role of tryptophan depletion in T cell suppression by macrophages,”Immunology92(supp. 1):7 (1997).
Aune and Pogue, “Inhibition of tumor cell growth by interferon-gamma is mediated by two distinct mechanisms dependent upon oxygen tension: induction of tryptophan degradation and depletion of intracellular nicotinamide adenine dinucleotide,”J. Clin. Invest. 84:863-875 (1989).
Blume, et al., “Triple Helix Formation by Purine-rich Oligonucleotides Targeted to the Human Dihydrofolate Reductase Promoter,”Nucl. Acids Res. 20:1777-1784 (1992).
Burke, et al., “The role of indoleamine 2,3-dioxygenase in the anti-tumour activity of human interferon-gamma in vivo,”Int J Cancer. 60(1):115-22 (1995).
Carlin, et al., “Interferon-induced indoleamine 2,3-dioxygenase activity in human mononuclear phagocytes,”J Leukoc Biol. 45(1):29-34 (1989).
Casciari, et al., “Glucose diffusivity in multicellular tumor spheroids,”Cancer Res. 48:3905-3909 (1988).
Cheng and Prusoff Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction.Biochem. Pharmacol. 22: 3099-3108 (1973).
Cooney, et al., “Site-Specific Oligonucleotide Binding Represses Transcription of the Human c-myc Gene in Vitro,”Science241: 456-459 (1988).
Crooke, “Progress Toward Oligonucleotide Therapeutics: Pharmacodynamic Properties,”FASEB J. 7: 533-539 (1993).
Duval-Valentin, et al., “Specific Inhibition of Transcription by Triple Helix-Forming Oligonucleotides,”Proc. Natl. Acad. Sci. USA, 89: 504-508 (1992).
Fleckner, et al., “Differential regulation of the human, interferon inducible tryptophanyl-tRNA synthetase by various cytokines in cell lines,”Cytokine7: 70-77 (1995).
Fleckner, et al., “Human interferon gamma potently induces the synthesis of a 55-kDa protein (gamma 2) highly homologous to rabbit peptide chain release factor and bovine tryptophanyl-tRNA synthetase,”Proc Natl Acad Sci U S A. 88(24):11520-4 (1991).
Grigoriev, et al., “A Triple Helix-forming Oligonucleotide-Intercalator Conjugate Acts as a Transcriptional Repressor via Inhibition of NF KB Binding to Interleukin-2 Receptor &agr;-Regulatory Sequence,”J. Biol. Chem. 267: 3389-3395 (1992).
Gupta, et al., “Antiparasitic and antiproliferative effects of indoleamine 2,3-dioxygenase enzyme expression in human fibroblasts,”Infect. Immun. 62: 2277
Mellor Andrew
Munn David
Medical College of Georgia Research Institute Inc.
Mueting Raasch & Gebhardt, P.A.
Pak Michael
LandOfFree
High-affinity tryptophan transporter does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with High-affinity tryptophan transporter, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and High-affinity tryptophan transporter will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2833614